erythromycin has been researched along with docetaxel anhydrous in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Collins, JM | 1 |
| Baker, LH; Bruno, R; Hirth, J; Schott, A; Strawderman, M; Watkins, PB | 1 |
| Booth, R; Clarke, SJ; Cullinane, C; Francis, P; Hatzimihalis, A; Michael, M; Milner, A; O'Kane, C; Schlicht, S | 1 |
1 review(s) available for erythromycin and docetaxel anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for erythromycin and docetaxel anhydrous
| Article | Year |
|---|---|
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Erythromycin; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Orosomucoid; Paclitaxel; Sarcoma; Soft Tissue Neoplasms; Taxoids | 2000 |
Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.
Topics: Adult; Aged; Antineoplastic Agents; Antipyrine; Area Under Curve; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Dose-Response Relationship, Drug; Erythromycin; Female; Humans; Male; Middle Aged; Phenotype; Taxoids | 2012 |
2 other study(ies) available for erythromycin and docetaxel anhydrous
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Cytochrome P-450 and other determinants of pharmacokinetics, toxicity, and efficacy in humans.
Topics: Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Erythromycin; Humans; Neoplasms; Oxidoreductases, N-Demethylating; Paclitaxel; Taxoids; Treatment Outcome | 2000 |